BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kim S, Kim KH, Kim BK, Park JY, Ahn SH, Kim DY, Kim SU. Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma. J Gastroenterol Hepatol 2021;36:1317-25. [PMID: 33217054 DOI: 10.1111/jgh.15355] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
Number Citing Articles
1 Wang S, Wang Y, Yu J, Wu H, Zhou Y. Lenvatinib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Cancers 2022;14:5525. [DOI: 10.3390/cancers14225525] [Reference Citation Analysis]
2 Tamaki N, Tada T, Kurosaki M, Yasui Y, Ochi H, Mashiba T, Sakamoto A, Marusawa H, Narita R, Uchida Y, Akahane T, Kondo M, Mori N, Takaki S, Tsuji K, Kobashi H, Kusakabe A, Furuta K, Arai H, Nonogi M, Ogawa C, Sato T, Tamada T, Nakamura S, Hasebe C, Tsuchiya K, Izumi N. Optimal threshold of alpha-fetoprotein response in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab. Invest New Drugs 2022. [PMID: 36152108 DOI: 10.1007/s10637-022-01303-w] [Reference Citation Analysis]
3 Choi NR, Kim JY, Hong JH, Hur MH, Cho H, Park MK, Kim J, Lee YB, Cho EJ, Lee JH, Yu SJ, Yoon JH, Kim YJ. Comparison of the outcomes between sorafenib and lenvatinib as the first-line systemic treatment for HBV-associated hepatocellular carcinoma: a propensity score matching analysis. BMC Gastroenterol 2022;22:135. [PMID: 35337274 DOI: 10.1186/s12876-022-02210-3] [Reference Citation Analysis]
4 Maeda H, Miura K, Morimoto N, Watanabe S, Tsukui M, Takaoka Y, Nomoto H, Goka R, Sato N, Morishima K, Sakuma Y, Sata N, Fukushima N, Isoda N, Yamamoto H. Conventional Therapies Do Not Prolong the Prognosis of Hepatocellular Carcinoma Patients with Extrahepatic Metastases under Receiving of Tyrosine Kinase Inhibitors. Cancers (Basel) 2022;14:752. [PMID: 35159018 DOI: 10.3390/cancers14030752] [Reference Citation Analysis]
5 郑 小. A Meta-Analysis of the Efficacy and Safety of Lenvatinib versus Sorafenib in Patients with Unresectable Liver Cancer. ACM 2022;12:2559-2567. [DOI: 10.12677/acm.2022.124369] [Reference Citation Analysis]
6 Tanoue K, Kawasaki Y, Yamasaki Y, Iino S, Sakoda M, Mataki Y, Idichi T, Kita Y, Hozaka Y, Nakajo A, Arigami T, Kurahara H, Ohtsuka T. Postoperative recurrence with right cervical lymph node metastasis in hepatocellular carcinoma: a case report. Surg Case Rep 2021;7:260. [PMID: 34918186 DOI: 10.1186/s40792-021-01352-y] [Reference Citation Analysis]
7 Kuo YH, Lu SN, Chen YY, Kee KM, Yen YH, Hung CH, Hu TH, Chen CH, Wang JH. Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. Front Oncol 2021;11:737767. [PMID: 34760699 DOI: 10.3389/fonc.2021.737767] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
8 Lenvatinib/sorafenib. Reactions Weekly 2021;1860:213-213. [DOI: 10.1007/s40278-021-97668-z] [Reference Citation Analysis]